DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Rhea-AI Summary

Illumina (NASDAQ: ILMN) on April 16, 2026 launched DRAGEN v4.5, expanding germline, oncology, and multiomic analysis with support for TruPath Genome and the 5-base assay.

Key gains: ~20% reduction in germline small-variant errors versus v4.4, expanded pangenome including Middle Eastern genomes, structural-variant calling for 5-base, ML-driven somatic calling, >90% FFPE SNV false-positive reduction, and oncovirus detection (100% expected detections plus 18 additional).

Positive

• Germline error reduction ~20% vs v4.4
• FFPE false positives reduced >90% (SNVs) and >87% (indels)
• TruPath support resolves 15 highly homologous medically relevant genes
• Pangenome expansion adds Middle Eastern genomes to reduce ancestry bias
• 5-base SV calling adds structural-variant detection for germline and somatic

Negative

• Release includes forward-looking statements and outcome risks that could affect adoption
• No commercial pricing, revenue guidance, or binding customer contracts disclosed

News Market Reaction – ILMN

+0.35%

+0.35% Session close to close

In the Apr 16 session, ILMN gained 0.35%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement showcases DRAGEN v4.5 as a major software expansion, adding pangenome personalizat...

Analysis

This announcement showcases DRAGEN v4.5 as a major software expansion, adding pangenome personalization, machine-learning-driven somatic analysis, and multiomic features that cut FFPE false positives by over 90% for some variants. It builds on earlier collaborations in preventive genomics and oncology, and arrives ahead of Illumina’s upcoming earnings release. Investors may watch future disclosures and adoption indicators to see how these capabilities translate into revenue, margins, and competitive positioning within diagnostics and research workflows.

Key Figures

Error reduction: 20% reduction Homologous genes: 15 genes FFPE SNV reduction: Over 90% +5 more

8 metrics

Error reduction 20% reduction Germline small variant false positives and false negatives vs DRAGEN v4.4

Homologous genes 15 genes Highly homologous, medically relevant genes resolved by TruPath support

FFPE SNV reduction Over 90% Reduction in FFPE-associated false positives for single nucleotide variants

FFPE indel reduction Over 87% Reduction in FFPE-associated false positives for indels

Oncovirus detection 100% expected Detection of expected oncoviruses in internal DRAGEN v4.5 tests

Additional oncoviruses 18 oncoviruses Extra oncoviruses identified beyond expected set in internal tests

Annual meeting date May 21, 2026 Virtual annual meeting date from recent DEF 14A filing

2025 Revenue $4.34B 2025 revenue, flat year over year, from DEF 14A

Historical Context

5 past events · Latest: Apr 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 14	Data partnership	Positive	+2.6%	Large-scale pediatric genomics partnership using DRAGEN v4.4 and cloud analytics.
Apr 09	Earnings timing	Neutral	-2.2%	Announcement of date and webcast details for Q1 2026 financial results.
Apr 02	Board changes	Neutral	+0.6%	Planned retirement of three directors and nomination of David P. King.
Mar 18	Oncology pact	Positive	+1.8%	Expanded collaboration with Labcorp to broaden precision oncology testing access.
Mar 16	Preventive genomics	Positive	+0.5%	Consortium with Veritas Genetics to integrate whole-genome sequencing in preventive care.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Illumina product and partnership news has generally coincided with positive next-day moves, suggesting the market often reacts constructively to strategic and technology updates.

Recent Company History

Over the past month, Illumina has reported several strategic and technology-focused developments. On Mar 16 and Mar 18, it announced collaborations in preventive genomics and precision oncology, both followed by positive moves. An April 2 Board refresh and an April 9 earnings date notice had modest to mixed reactions. Most recently, the April 14 pediatric cancer and rare disease data partnership using DRAGEN v4.4 saw a 2.65% gain. Today’s DRAGEN v4.5 launch extends this software-focused narrative across germline, oncology, and multiomic workflows.

Key Terms

multiomic, epigenetic, methylation, structural variant, +4 more

8 terms

multiomic medical

"As genomic researchers contend with complex regions of the genome, degraded samples, and multiomic data types,"

Multiomic describes the combined analysis of different layers of biological information—such as genes, proteins and small molecules—to build a more complete picture of how cells and diseases work. Like viewing a problem from several camera angles instead of one, it can reveal stronger drug targets, clearer diagnostic markers and better predictions of who will benefit from a therapy, which helps investors assess scientific validity, market potential and development risk.

epigenetic medical

"enabling more integrated genetic and epigenetic insightIntroduces machine-learning-driven somatic analysis"

Epigenetic describes changes that alter how genes are turned on or off without changing the underlying DNA sequence, similar to flipping light switches or adjusting software settings that control a machine. For investors, epigenetic mechanisms matter because they create new targets for drugs, diagnostics, and therapies that can modify disease processes or patient responses, potentially leading to novel products, market opportunities, and long-term revenue streams.

methylation medical

"His team found that 5-base provided highly accurate methylation information and detected abnormal"

Methylation is a chemical process where small tags called methyl groups attach to DNA or proteins, altering how genes are read without changing the underlying genetic code. Investors monitor methylation because patterns can serve as diagnostic markers, drug targets, or measures of treatment response in biotech and healthcare—think of them as sticky notes or light switches that change biological behavior and can affect a product’s development, approval and market value.

structural variant medical

"Significantly expands multiomic analysis, with structural variant calling and improved small variant accuracy"

A structural variant is a change in the physical layout of a stretch of DNA—such as a piece being deleted, duplicated, flipped, or moved to a new location—affecting segments large enough to alter how genes work. For investors, these changes can create or reveal disease causes, affect how well a therapy or diagnostic works, and influence regulatory and commercial prospects; think of it like major edits to a building’s blueprint that change its function and value.

somatic medical

"Machine learning expands Illumina's 5-base solution: The release introduces structural variant calling for both germline and somatic applications"

Relating to the body's non-reproductive cells, 'somatic' describes changes, tests or therapies that affect ordinary tissue cells rather than eggs or sperm. For investors, somatic matters because treatments or diagnostics aimed at these cells — for example targeting a tumor's specific mutations — determine regulatory pathways, market size and liability differently than interventions that alter the inherited genome; think of fixing a part on a car versus changing the car's original blueprint.

germline medical

"This release enhances DRAGEN's strong germline foundation with expanded pangenome representation"

Germline describes genetic changes that occur in reproductive cells (sperm or eggs) and therefore can be passed to future generations. Think of it as an inherited blueprint update rather than a one‑off repair in a single person; that permanence raises different scientific, ethical and regulatory questions. For investors, germline work matters because it affects long‑term safety concerns, approval pathways, public acceptance and potential market size for genetic therapies.

formalin fixed paraffin embedded (ffpe) medical

"Formalin fixed paraffin embedded (FFPE) samples present substantial technical noise that can make it difficult"

A laboratory method that preserves biological tissue by first treating it with formalin to stop decay and then embedding it in paraffin wax, creating a stable block that can be sliced for microscopy or molecular tests. For investors, FFPE matters because these archived samples are the raw material for diagnostic test development, pathology validation, and biomarker research; their preservation method affects the quality and reliability of genetic and protein analyses, which can influence product pipelines and regulatory outcomes.

oncovirus medical

"Additionally, v4.5 debuts robust oncovirus detection. Certain viruses, such as human papillomavirus (HPV),"

An oncovirus is a virus that can trigger the development of cancer by changing how cells grow and divide; think of it like a spark that can start a slow-burning fire in vulnerable tissue. For investors, oncoviruses matter because they create needs for diagnostics, vaccines and treatments, influence regulatory and reimbursement decisions, and can affect public health spending and market demand in biotech and healthcare sectors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research

New pangenome representation, default personalization, and machine learning features boost analytical capabilities across applications  

SAN DIEGO, April 16, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software (v4.5), one of the most substantial expansions of the software's capabilities to date. As genomic researchers contend with complex regions of the genome, degraded samples, and multiomic data types, DRAGEN v4.5 delivers new ways to reduce noise, improve accuracy, and extract biological signals, giving researchers greater discovery power to fuel findings in rare disease and oncology.

This release enhances DRAGEN's strong germline foundation with expanded pangenome representation and personalization, further improving variant calling accuracy and performance in challenging genomic regions. v4.5 provides analytical support for Illumina TruPath™ Genome, resolving challenging-to-map regions of the genome.

"These advances expand the scope of biological questions researchers can address across germline, oncology, and multiomic applications—while maintaining the speed, scale, and operational consistency expected from DRAGEN," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. "BioInsight is all about making bioinformatics accessible, reliable, and scalable, whether you are a researcher seeking insights into rare disease or a pharma partner pursuing drug discovery from datasets."

DRAGEN v4.5 key updates

• Significantly expands multiomic analysis, with structural variant calling and improved small variant accuracy for Illumina's 5-base solution, enabling more integrated genetic and epigenetic insight
• Introduces machine-learning-driven somatic analysis and expands oncology insights with new capabilities like oncovirus detection
• Strengthens the scalable multiomic pipelines that support ambitious projects, like the recently announced Billion Cell Atlas

David Spencer, a researcher at Washington University School of Medicine in St. Louis, applied v4.5 to his trial of Illumina's 5-base assay on acute myeloid leukemia, or AML, samples. Genetic mutations detected at diagnosis are important predictors of clinical outcomes in AML. Persistent mutations in remission are also predictive of relapse. Spencer is exploring whether epigenetic changes can be used as biomarkers to further improve predictions of relapse. His team found that 5-base provided highly accurate methylation information and detected abnormal epigenetic patterns in samples with clonal disease in remission, highlighting the potential of integrated genetic and epigenetic analysis to improve disease characterization and monitoring.

"Illumina 5-base and DRAGEN v4.5 combine variant detection and methylation with added structural-variant calling capabilities, expanding the set of genomic changes that can be explored as potential biomarkers in AML samples," said Spencer.

Personalization, machine learning are among new features of DRAGEN v4.5

Advances in v4.5 enhance secondary analysis in genomic and multiomic workflows.  

• New algorithms support Illumina TruPath™ Genome: v4.5 introduces analytical support for TruPath, leveraging algorithmic advances to resolve 15 highly homologous, medically-relevant genes for rare disease research.
• Personalization improves germline variant calling: Personalization by default further reduces germline small variant errors, delivering approximately a 20% reduction in false positives and false negatives compared to v4.4.
• Pangenome better reflects global genomic diversity and reduces ancestry-related bias: The addition of Middle Eastern reference genomes expands the DRAGEN pangenome to better represent global population diversity, improving mapping and variant calling across underrepresented ancestries. In parallel, targeted improvements to the SMN1 variant caller enable detection of silent carriers, addressing a known source of underdiagnosis in certain populations.
• Machine learning expands Illumina's 5-base solution: The release introduces structural variant calling for both germline and somatic applications of 5-base, alongside improved germline small variant accuracy and personalization enabled by data specificity and machine learning. Illumina Connected Annotation further supports these analyses by highlighting genomic regions of interest informed by methylation data, simplifying interpretation of complex multiomic datasets.

Oncology features bring bioinformatics power to complex cancer questions

Formalin fixed paraffin embedded (FFPE) samples present substantial technical noise that can make it difficult to identify relevant variants. v4.5's machine-learning-driven somatic small variant calling reduces FFPE-associated false positives by over 90% for single nucleotide variants and over 87% for indels—improving sensitivity without increasing runtime or computational burden. Opt-in machine learning separates true variants and background artifacts, improving sensitivity at low tumor purity. This enables more reliable detection of biologically relevant variants in challenging samples.

Additionally, v4.5 debuts robust oncovirus detection. Certain viruses, such as human papillomavirus (HPV), can drive cancer development by disrupting normal cellular control mechanisms, sometimes through integration of viral DNA into the host genome. In internal tests, v4.5 detected 100% of expected oncoviruses and identified 18 additional oncoviruses, showcasing the software's sensitivity for high-risk strains of HPV and Epstein-Barr Virus. Researchers can use this information to develop new tests and targets for oncovirus-driven cancers.

The software is available via on-premises servers and in the cloud. Register today for our April 30 technical webinar to see DRAGEN v4.5 in action and read the technical blog to learn more.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; and (iii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content:https://www.prnewswire.com/news-releases/dragen-v4-5-supports-illuminas-new-trupath-genome-and-5-base-assays-drives-insights-across-germline-oncology-and-multiomic-workflows-302744328.html

SOURCE Illumina, Inc.

FAQ

What does DRAGEN v4.5 mean for Illumina (ILMN) customers using TruPath Genome?

DRAGEN v4.5 adds analytical support for TruPath Genome, improving mapping in difficult regions. According to the company, v4.5 resolves 15 highly homologous medically relevant genes to boost rare-disease variant detection and accuracy.

How much does DRAGEN v4.5 improve germline variant accuracy compared to v4.4 for ILMN users?

DRAGEN v4.5 yields about a 20% reduction in false positives and false negatives versus v4.4. According to the company, personalization-by-default drives this improvement in germline small-variant calling.

How does DRAGEN v4.5 improve cancer sample analysis for Illumina (ILMN) oncology customers?

v4.5 uses machine learning to cut FFPE-associated false positives by over 90% for SNVs and over 87% for indels. According to the company, this improves sensitivity at low tumor purity without raising runtime.

What new multiomic capabilities does DRAGEN v4.5 bring to Illumina's 5-base assay users?

v4.5 introduces structural-variant calling and improved small-variant accuracy for the 5-base solution, enabling integrated genetic and methylation analyses. According to the company, Connected Annotation highlights regions informed by methylation for interpretation.

What evidence does Illumina cite for DRAGEN v4.5 oncovirus detection performance?

In internal tests, v4.5 detected 100% of expected oncoviruses and identified 18 additional oncoviruses. According to the company, these results demonstrate sensitivity for high-risk HPV and Epstein-Barr Virus detection.